Kiedy wybieram lizynopryl? Punkt widzenia kardiologa i farmakologa klinicznego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
lizynopryl, nadciśnienie tętnicze, choroba wieńcowa, niewydolność serca, cukrzyca, przewlekła choroba nerek
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leczenie pacjentów z nadciśnieniem tętniczym i chorobami współistniejącymi stanowi duże wyzwanie wymagające zindywidualizowanej farmakoterapii. Inhibitory enzymu konwertazy angiotensyny odgrywają niezwykle ważną rolę w terapii chorób układu sercowo-naczyniowego. Ich skuteczność wiąże się nie tylko z działaniem hipotensyjnym, ale także z protekcyjnym wpływem na inne ważne dla funkcjonowania organizmu narządy. Artykuł omawia praktyczne wskazania do stosowania jednego z ich przedstawicieli – lizynoprylu. Liczne badania jednoznacznie wykazały korzyść z jego stosowania w nadciśnieniu tętniczym, niewydolności serca, we wczesnej fazie zawału serca oraz u pacjentów z cukrzycą i ze współistniejącymi powikłaniami ze strony nerek.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lewandowski, J., & Strzelczyk, J. (2024). Kiedy wybieram lizynopryl? Punkt widzenia kardiologa i farmakologa klinicznego . Medycyna Faktów , 17(1(62), 103-108. https://doi.org/10.24292/01.MF.0124.16
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Mancia G, Kreutz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874-2071.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23): 2981-97.
3. Cushman WC, Ford CE, Einhorn PT et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008; 10(10): 751-60.
4. Liang L, Kung JY, Mitchelmore B et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2022; 24(5): 536-54.
5. Beckett NS, Peters R, Fletcher AE et al.; for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358.
6. Zuanetti G, Latini R, Maggioni AP et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 1997; 96(12): 4239-45.
7. Borghi C, Omboni S, Reggiardo G et al. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart. 2015; 2(1): e000220.
8. Boden WE, O’Rourke RA, Teo KK et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006; 151(6): 1173-9.
9. Kim YH, Her AY, Jeong MH et al. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents. Atherosclerosis. 2019; 289: 109-17.
10. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999; 100(23): 2312-8.
11. McDonagh TA, Metra M, Adamo M et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-726.
12. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321(7274): 1440-4.
13. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 2: 1787-92.
14. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998; 351: 28-31.
15. Farsang C.; HAMLET Trial Investigation. Advantages of lisinopril amlodipine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia. 2004; 8: 72-8.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23): 2981-97.
3. Cushman WC, Ford CE, Einhorn PT et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008; 10(10): 751-60.
4. Liang L, Kung JY, Mitchelmore B et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2022; 24(5): 536-54.
5. Beckett NS, Peters R, Fletcher AE et al.; for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358.
6. Zuanetti G, Latini R, Maggioni AP et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation. 1997; 96(12): 4239-45.
7. Borghi C, Omboni S, Reggiardo G et al. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart. 2015; 2(1): e000220.
8. Boden WE, O’Rourke RA, Teo KK et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006; 151(6): 1173-9.
9. Kim YH, Her AY, Jeong MH et al. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents. Atherosclerosis. 2019; 289: 109-17.
10. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999; 100(23): 2312-8.
11. McDonagh TA, Metra M, Adamo M et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-726.
12. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321(7274): 1440-4.
13. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 2: 1787-92.
14. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998; 351: 28-31.
15. Farsang C.; HAMLET Trial Investigation. Advantages of lisinopril amlodipine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia. 2004; 8: 72-8.